DAVID A SCHEINBERG, MD
Osteopathic Medicine at York Ave, New York, NY
License number
New York 156274
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(212) 639-2000
Personal information
See more information about DAVID A SCHEINBERG at radaris.comName
Address
Phone
25 S Remsen St, Monsey, NY 10952
325 Central Park W APT 6N, New York, NY 10025
71 Burda Ln, New City, NY 10956
968 Stratford Ct, N Bellmore, NY 11710
New York, NY
Organization information
See more information about DAVID A SCHEINBERG at bizstanding.comDavid Scheinberg MD
1275 York Ave, New York, NY 10065
Industry:
Internist
Phone:
(800) 525-2225 (Phone)
David A. Scheinberg
David Scheinberg LLC
325 Central Park W, New York, NY 10025
Status:
Inactive
Industry:
Nonclassifiable Establishments
Professional information
Bismuth-213 Generator And Uses Thereof
US Patent:
6603127, Aug 5, 2003
Filed:
Dec 19, 2000
Appl. No.:
09/647491
Inventors:
David Scheinberg - New York NY
Ronald D. Finn - Rye NY
Dangshe Ma - New York NY
Michael R. McDevitt - New York NY
Ronald D. Finn - Rye NY
Dangshe Ma - New York NY
Michael R. McDevitt - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C01G 2900
US Classification:
250432PD, 423 2, 423 6, 423 87, 423249, 210682, 424 111, 252645
Abstract:
The present invention provides a generator capable of producing therapeutic Bismuth-213 doses. Also disclosed are methods of preparing Bismuth-213-labeled compounds using such generator and applications of the labeled compounds.
Antibodies With Increased Binding Affinity
US Patent:
6350861, Feb 26, 2002
Filed:
May 23, 1997
Appl. No.:
08/862871
Inventors:
Man Sung Co - Cupertino CA
David A. Scheinberg - New York NY
Cary L. Queen - Los Altos CA
David A. Scheinberg - New York NY
Cary L. Queen - Los Altos CA
Assignee:
Protein Design Labs, Inc. - Mountain View CA
Memorial Sloan Kettering Cancer Center - New York NY
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
C07K 1630
US Classification:
53038885, 5303871, 5303873, 5303888, 4241561
Abstract:
The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.
Methods Of Protection From Toxicity Of Alpha Emitting Elements During Radioimmunotherapy
US Patent:
2004019, Sep 30, 2004
Filed:
Mar 23, 2004
Appl. No.:
10/806905
Inventors:
David Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Jaspreet Jaggi - New York NY, US
Michael McDevitt - Bronx NY, US
Jaspreet Jaggi - New York NY, US
International Classification:
A61K051/00
US Classification:
424/001490
Abstract:
Provided herein are methods of reducing nephrotoxicityfrom at least one alpha particle-emitting daughter of actinium-225 during radioimmunotherapeutic treatment for a pathophysiological condition, methods of improving radioimmunotherapeutic treatment of cancer and methods of increasing the therapeuticindex of an actinium-225 radioimmunoconjugate during treatment of a pathophysiological condition. Adjuvants effective for preventing accumulation of Ac daughters within the kidneys are administered during treatment with an actinium-225 radioimmunoconjugate to reduce nephrotoxicity. Examples of adjuvants are chelators, diuretics and/or competitive metal blockers.
Wt1 Hla Class Ii-Binding Peptides And Compositions And Methods Comprising Same
US Patent:
2010011, May 6, 2010
Filed:
Oct 17, 2006
Appl. No.:
12/083731
Inventors:
David A. Scheinberg - New York NY, US
Rena May - Richmond VA, US
Rena May - Richmond VA, US
Assignee:
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
International Classification:
A61K 39/00, C07K 14/435
US Classification:
4241851, 530326
Abstract:
This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
Suicide Tetramers And Uses Thereof
US Patent:
2003022, Dec 11, 2003
Filed:
May 30, 2003
Appl. No.:
10/448647
Inventors:
David Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Michael McDevitt - Bronx NY, US
International Classification:
A61K051/00, C07K014/74
US Classification:
424/001690, 530/350000
Abstract:
The present invention provides a cytotoxic MHC I conjugate comprising a cytotoxic moiety, biotinylated MHC I monomers which each comprise an antigenic peptide and streptavidin, bound to the cytotoxic moiety or to a biotinylated cytotoxic moiety and to the biotinylated MHC I monomers. Alternative constructs comprising a cytotoxic moiety and biotinylated MHC I monomers where each monomer comprises an antibody fragment also are provided. The cytotoxic moiety may comprise an 225Ac radionuclide or other cytotoxin. Further provided are methods of killing CD8T cell clonal populations.
Alpha Emitting Constructs And Uses Thereof
US Patent:
7736651, Jun 15, 2010
Filed:
Nov 24, 2000
Appl. No.:
09/721864
Inventors:
David Scheinberg - New York NY, US
Dangshe Ma - New York NY, US
Michael R. McDevitt - Bronx NY, US
George Sgouros - New York NY, US
Dangshe Ma - New York NY, US
Michael R. McDevitt - Bronx NY, US
George Sgouros - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 39/395
US Classification:
4241781, 4241551, 5303871, 5303913
Abstract:
The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.
Liposomal Encapsulation Of Alpha Particle Emittors And Uses Thereof
US Patent:
2004016, Aug 26, 2004
Filed:
Nov 24, 2003
Appl. No.:
10/720904
Inventors:
George Sgouros - Ellicott City MD, US
James Thomas - Cedar Crest NM, US
David Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Stavroula Sofou - New York NY, US
James Thomas - Cedar Crest NM, US
David Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Stavroula Sofou - New York NY, US
Assignee:
Sloan Kettering Institute for Cancer Research
International Classification:
A61M036/14, A61K051/00
US Classification:
424/001650
Abstract:
The present invention provides targeted delivery of alpha particle-emitting radionuclides and their alpha-emitting progeny using liposomal encapsulation to reduce the loss of daughter radionuclides from the targeting vehicle and, therefore, from the tumor site. Also provided are encapsulated alpha particle-emitting radionuclides.
Synthetic Hla Binding Peptide Analogues And Uses Thereof
US Patent:
2010023, Sep 23, 2010
Filed:
Oct 6, 2009
Appl. No.:
12/574555
Inventors:
David A. Scheinberg - New York NY, US
International Classification:
A61K 35/26, C12N 5/00, C12N 5/02, A61K 38/08, A61K 31/7088, C07K 7/08, C07K 7/06, C07K 14/00, C07K 14/76, A61P 35/00
US Classification:
424 9371, 435325, 435375, 514 193, 514 44 R, 530327, 530328, 530350, 530362
Abstract:
The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The synthetic peptide may be derived form native peptides comprising a breakpoint region of the WT1 protein.
Method Of Inhibitor Design And Identification Using A 3-D Structure Of Human Peptide Deformylase
US Patent:
7747395, Jun 29, 2010
Filed:
Apr 13, 2007
Appl. No.:
11/787237
Inventors:
David A. Scheinberg - New York NY, US
Yehuda Goldgur - Fair Lawn NJ, US
Yueming Li - New York NY, US
Yehuda Goldgur - Fair Lawn NJ, US
Yueming Li - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
G01N 31/00, C12Q 1/34, C12Q 1/00
US Classification:
702 27, 435 18, 435 4, 435 5, 435 721, 435 722, 435 732
Abstract:
The present invention provides the three-dimensional structure of human mitochondrial peptide deformylase (HsPDF) protein, and HsPDF complexed to a binding compound, such as a PDF inhibitor. This crystallographic information will aid in the identification and development of novel binding compounds of HsPDF and other PDF family members which have anti-bacterial, anti-viral, anti-parasitical, anti-inflammatory, and/or anti-cancer activity.
Compositions And Methods For Treating Cancer And Other Diseases
US Patent:
2012022, Sep 6, 2012
Filed:
Nov 16, 2010
Appl. No.:
13/510221
Inventors:
David A. Scheinberg - New York NY, US
International Classification:
A61K 31/7105, C07K 16/18, C12N 15/113, A61K 39/395, A61K 31/713, A61P 35/00, A61P 37/00, A61P 35/02, A61P 19/04, A61P 3/10, A61P 29/00, A61P 17/06, A61P 17/14, A61P 27/02, C07H 1/00, C07H 21/02
US Classification:
4241781, 536 231, 5303917, 536 245, 514 44 R, 514 44 A, 536 253
Abstract:
Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3′ or 5′ polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided.